{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T15:11:24Z","timestamp":1783177884934,"version":"3.54.6"},"reference-count":59,"publisher":"Ovid Technologies (Wolters Kluwer Health)","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:p>The therapeutic landscape for obesity and type 2 diabetes mellitus (T2DM) is being reshaped by glucagon-like peptide-1 receptor agonists (GLP-1 RAs). Orforglipron (LY3502970) represents a significant evolution in this class. Given the limitations of injectable GLP-1 RAs and the administration constraints of oral semaglutide, orforglipron offers a major convenience advantage: it is a small molecule with ~79% oral bioavailability that requires no food or water restrictions. Mechanistically, it acts by stimulating cyclic adenosine monophosphate without inducing \u03b2-arrestin recruitment, thus potentially limiting receptor desensitization and tachyphylaxis. Phase 3 trials demonstrated potent, dose-dependent efficacy. In the ACHIEVE-3 head-to-head trial (T2DM), orforglipron 36\u2009mg proved superior to oral semaglutide 14\u2009mg, delivering significantly greater reductions in hemoglobin A1c (\u20132.2% vs \u20131.4%) and body weight (\u20139.2% vs \u20135.3%). In the ATTAIN-2 trial (obesity and T2DM), the same dose achieved 10.5% mean weight loss. The safety profile is consistent with the GLP-1 RA class, dominated by manageable gastrointestinal events mitigated by slow dose escalation. A nondose-dependent heart rate increase and a small signal for mild pancreatitis were observed. A class-specific concern exists regarding increased ventricular arrhythmia risk in patients with heart failure with reduced ejection fraction treated with conventional GLP-1 RAs.<\/jats:p>","DOI":"10.1097\/crd.0000000000001139","type":"journal-article","created":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T05:00:40Z","timestamp":1765861240000},"update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":4,"title":["Orforglipron: A Novel Oral GLP-1 Agonist for the Treatment of Obesity and Diabetes"],"prefix":"10.1097","author":[{"given":"Ashwin A.","family":"Pillai","sequence":"first","affiliation":[{"name":"Department of Cardiology, Virginia Commonwealth University, Richmond, VA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashish M.","family":"Sharma","sequence":"additional","affiliation":[{"name":"Department of Hospital Medicine, Yale New Haven Hospital, New Haven, CT"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hussein","family":"Krayem","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Virginia Commonwealth University, Richmond, VA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William H.","family":"Frishman","sequence":"additional","affiliation":[{"name":"Department of Medicine Westchester Medical Center and New York Medical College, Valhalla, NY."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wilbert S.","family":"Aronow","sequence":"additional","affiliation":[{"name":"Department of Medicine Westchester Medical Center and New York Medical College, Valhalla, NY."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,12,16]]},"reference":[{"key":"R2-20251216","article-title":"Obesity and severe obesity prevalence in adults: United States, August 2021\u2013August 2023.","author":"Emmerich","year":"2024","journal-title":"NCHS Data Brief"},{"key":"R3-20251216","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1056\/NEJM199708283370901","article-title":"Valvular heart disease associated with fenfluramine-phentermine.","volume":"337","author":"Connolly","year":"1997","journal-title":"N Engl J Med"},{"key":"R4-20251216","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1056\/NEJMoa1003114","article-title":"Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects.","volume":"363","author":"James","year":"2010","journal-title":"N Engl J Med"},{"key":"R5-20251216","doi-asserted-by":"crossref","first-page":"173","DOI":"10.2337\/cd16-0005","article-title":"More than 7 years of hindsight: revisiting the FDA\u2019s 2008 guidance on cardiovascular outcomes trials for type 2 diabetes medications.","volume":"34","author":"Regier","year":"2016","journal-title":"Clin Diabetes"},{"key":"R6-20251216","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes.","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"key":"R7-20251216","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","article-title":"Semaglutide and cardiovascular outcomes in obesity without diabetes.","volume":"389","author":"Lincoff","year":"2023","journal-title":"N Engl J Med"},{"key":"R8-20251216","doi-asserted-by":"crossref","first-page":"216","DOI":"10.4183\/aeb.2022.216","article-title":"Weight loss effect of sodium-glucose cotransporter-2 (SGLT2) inhibitors in patients with obesity without diabetes: a systematic review.","volume":"18","author":"Pratama","year":"2022","journal-title":"Acta Endocrinol (Buchar)"},{"key":"R9-20251216","doi-asserted-by":"crossref","DOI":"10.1097\/CRD.0000000000000832","article-title":"The effects of metformin on weight loss, cardiovascular health, and longevity.","author":"Pillai","year":"2024","journal-title":"Cardiol Rev"},{"key":"R10-20251216","doi-asserted-by":"crossref","first-page":"100933","DOI":"10.1016\/j.eclinm.2021.100933","article-title":"SGLT2 inhibitors decrease cardiovascular death and heart failure hospitalizations in patients with heart failure: a systematic review and meta-analysis.","volume":"36","author":"Cardoso","year":"2021","journal-title":"eClinicalMedicine"},{"key":"R11-20251216","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1007\/s00125-023-06057-5","article-title":"Cardiovascular and mortality outcomes with GLP-1 receptor agonists vs other glucose-lowering drugs in individuals with NAFLD and type 2 diabetes: a large population-based matched cohort study.","volume":"67","author":"Krishnan","year":"2024","journal-title":"Diabetologia"},{"key":"R12-20251216","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1038\/s41392-024-01931-z","article-title":"Glucagon-like peptide-1 receptor: mechanisms and advances in therapy.","volume":"9","author":"Zheng","year":"2024","journal-title":"Signal Transduct Target Ther"},{"key":"R13-20251216","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.beem.2009.03.005","article-title":"Mechanisms underlying the rapid degradation and elimination of the incretin hormones GLP-1 and GIP.","volume":"23","author":"Mentlein","year":"2009","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"R14-20251216","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1016\/S0140-6736(87)91194-9","article-title":"Glucagon-like peptide-1 7-36: a physiological incretin in man.","volume":"2","author":"Kreymann","year":"1987","journal-title":"Lancet"},{"key":"R15-20251216","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.1038\/ijosup.2014.4","article-title":"The class B G-protein-coupled GLP-1 receptor: an important target for the treatment of type-2 diabetes mellitus.","volume":"4","author":"Miller","year":"2014","journal-title":"Int J Obes Suppl"},{"key":"R16-20251216","doi-asserted-by":"crossref","first-page":"24278","DOI":"10.1039\/D2RA02784D","article-title":"Synthesis of the extracellular domain of GLP-1R by chemical and biotechnological approaches.","volume":"12","author":"Szolomajer","year":"2022","journal-title":"RSC Adv"},{"key":"R17-20251216","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1124\/pr.115.011395","article-title":"Glucagon-like peptide-1 and its class B G protein\u2013coupled receptors: a long march to therapeutic successes.","volume":"68","author":"de Graaf","year":"2016","journal-title":"Pharmacol Rev"},{"key":"R18-20251216","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1111\/bph.15462","article-title":"Glucagon\u2010like peptide\u20101 (GLP\u20101) receptor agonists and their cardiovascular benefits\u2014the role of the GLP\u20101 receptor.","volume":"179","author":"Helmst\u00e4dter","year":"2022","journal-title":"Br J Pharmacol"},{"key":"R19-20251216","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.1016\/S0140-6736(25)01375-3","article-title":"Semaglutide and cardiovascular outcomes by baseline and changes in adiposity measurements: a prespecified analysis of the SELECT trial.","volume":"406","author":"Deanfield","year":"2025","journal-title":"Lancet"},{"key":"R20-20251216","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1056\/NEJMoa2313917","article-title":"Semaglutide in patients with obesity-related heart failure and type 2 diabetes.","volume":"390","author":"Kosiborod","year":"2024","journal-title":"N Engl J Med"},{"key":"R21-20251216","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1016\/j.jchf.2024.12.004","article-title":"Glucagon-like peptide 1 receptor agonist is associated with improved survival in overweight heart failure patients.","volume":"13","author":"Karlstr\u00f6m","year":"2025","journal-title":"JACC Heart Fail"},{"key":"R22-20251216","doi-asserted-by":"crossref","first-page":"102573","DOI":"10.1016\/j.jchf.2025.102573","article-title":"Effects of glucagon-like peptide 1 receptor agonist initiation in patients with heart failure with reduced ejection fraction and implantable cardiac devices.","volume":"13","author":"Marques","year":"2025","journal-title":"JACC Heart Fail"},{"key":"R23-20251216","doi-asserted-by":"crossref","first-page":"102642","DOI":"10.1016\/j.jchf.2025.102642","article-title":"GLP-1 receptor agonists in heart failure with reduced ejection fraction?","volume":"13","author":"Litwin","year":"2025","journal-title":"JACC Heart Fail"},{"key":"R24-20251216","doi-asserted-by":"crossref","first-page":"2022","DOI":"10.1016\/j.jacc.2017.09.002","article-title":"Obesity and atrial fibrillation prevalence, pathogenesis, and prognosis.","volume":"70","author":"Lavie","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"R25-20251216","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/S0735-1097(25)00565-0","article-title":"Glp-1 receptor agonists and atrial fibrillation\/atrial flutter in patients with diabetes: a retrospective analysis.","volume":"85","author":"O\u2019Neill","year":"2025","journal-title":"JACC"},{"key":"R26-20251216","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.1016\/j.jacep.2024.03.031","article-title":"Effects of glucagon-like peptide-1 receptor agonists on atrial fibrillation recurrence after catheter ablation.","volume":"10","author":"Satti","year":"2024","journal-title":"JACC Clin Electrophysiol"},{"key":"R27-20251216","doi-asserted-by":"crossref","first-page":"910256","DOI":"10.3389\/fendo.2022.910256","article-title":"Effects of GLP-1 receptor agonists on arrhythmias and its subtypes in patients with type 2 diabetes: a systematic review and meta-analysis.","volume":"13","author":"Wei","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"key":"R28-20251216","doi-asserted-by":"crossref","first-page":"101102","DOI":"10.1016\/j.molmet.2020.101102","article-title":"GLP-1 receptor agonists in the treatment of type 2 diabetes\u2014state-of-the-art.","volume":"46","author":"Nauck","year":"2020","journal-title":"Mol Metab"},{"key":"R29-20251216","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1056\/NEJMoa2411528","article-title":"Once-weekly mazdutide in Chinese adults with obesity or overweight.","volume":"392","author":"Ji","year":"2025","journal-title":"N Engl J Med"},{"key":"R30-20251216","doi-asserted-by":"crossref","first-page":"e076410","DOI":"10.1136\/bmj-2023-076410","article-title":"Comparative effectiveness of GLP-1 receptor agonists on glycaemic control, body weight, and lipid profile for type 2 diabetes: systematic review and network meta-analysis.","volume":"384","author":"Yao","year":"2024","journal-title":"BMJ"},{"key":"R31-20251216","doi-asserted-by":"crossref","first-page":"4095","DOI":"10.1038\/s41598-018-22443-1","article-title":"Comparison of non-insulin antidiabetic agents as an add-on drug to insulin therapy in type 2 diabetes: a network meta-analysis.","volume":"8","author":"Yoon","year":"2018","journal-title":"Sci Rep"},{"key":"R32-20251216","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.2337\/dc13-3007","article-title":"Glucose-lowering effects and low risk of hypoglycemia in patients with maturity-onset diabetes of the young when treated with a GLP-1 receptor agonist: a double-blind, randomized, crossover trial.","volume":"37","author":"\u00d8stoft","year":"2014","journal-title":"Diabetes Care"},{"key":"R33-20251216","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1016\/j.kint.2022.12.028","article-title":"Post hoc analysis of SUSTAIN 6 and PIONEER 6 trials suggests that people with type 2 diabetes at high cardiovascular risk treated with semaglutide experience more stable kidney function compared with placebo.","volume":"103","author":"Tuttle","year":"2023","journal-title":"Kidney Int"},{"key":"R34-20251216","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1056\/NEJMoa1616011","article-title":"Liraglutide and renal outcomes in type 2 diabetes.","volume":"377","author":"Mann","year":"2017","journal-title":"N Engl J Med"},{"key":"R35-20251216","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/S2213-8587(24)00271-7","article-title":"Effects of GLP-1 receptor agonists on kidney and cardiovascular disease outcomes: a meta-analysis of randomised controlled trials.","volume":"13","author":"Badve","year":"2025","journal-title":"Lancet Diabetes Endocrinol"},{"key":"R36-20251216","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1007\/s40120-025-00724-y","article-title":"Are glucagon-like peptide-1 (GLP-1) receptor agonists central nervous system (CNS) penetrant: a narrative review.","volume":"14","author":"West","year":"2025","journal-title":"Neurol Ther"},{"key":"R37-20251216","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1007\/s11154-023-09807-3","article-title":"Effects of GLP-1 receptor agonists on neurological complications of diabetes.","volume":"24","author":"Garc\u00eda-Casares","year":"2023","journal-title":"Rev Endocr Metab Disord"},{"key":"R38-20251216","doi-asserted-by":"crossref","first-page":"114622","DOI":"10.1016\/j.physbeh.2024.114622","article-title":"Glucagon-like peptide 1 agonist and effects on reward behaviour: a systematic review.","volume":"283","author":"Badulescu","year":"2024","journal-title":"Physiol Behav"},{"key":"R39-20251216","doi-asserted-by":"crossref","first-page":"5338","DOI":"10.3390\/ijms26115338","article-title":"GLP-1 analogues in the neurobiology of addiction: translational insights and therapeutic perspectives.","volume":"26","author":"Marquez-Meneses","year":"2025","journal-title":"Int J Mol Sci"},{"key":"R40-20251216","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1111\/dom.12849","article-title":"Efficacy and safety of glucagon-like peptide-1 receptor agonists in type 2 diabetes: a systematic review and mixed-treatment comparison analysis.","volume":"19","author":"Htike","year":"2017","journal-title":"Diabetes Obes Metab"},{"key":"R41-20251216","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/s11894-025-00995-3","article-title":"Gastrointestinal motility effects of GLP-1 receptor agonists.","volume":"27","author":"Bellavance","year":"2025","journal-title":"Curr Gastroenterol Rep"},{"key":"R42-20251216","doi-asserted-by":"crossref","first-page":"6515","DOI":"10.1016\/S0021-9258(19)69015-0","article-title":"Pancreatic pre-proglucagons are encoded by two separate mRNAs.","volume":"256","author":"Lund","year":"1981","journal-title":"J Biol Chem"},{"key":"R43-20251216","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1038\/289511a0","article-title":"Cell-free synthesis and processing of multiple precursors to glucagon.","volume":"289","author":"Shields","year":"1981","journal-title":"Nature"},{"key":"R44-20251216","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1172\/JCI112855","article-title":"Insulinotropin: glucagon-like peptide I (7-37) co-encoded in the glucagon gene is a potent stimulator of insulin release in the perfused rat pancreas.","volume":"79","author":"Mojsov","year":"1987","journal-title":"J Clin Invest"},{"key":"R46-20251216","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1007\/s13300-019-0627-1","article-title":"Pancreatitis incidence in the exenatide BID, exenatide QW, and exenatide QW suspension development programs: pooled analysis of 35 clinical trials.","volume":"10","author":"Vetter","year":"2019","journal-title":"Diabetes Ther"},{"key":"R47-20251216","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1186\/s12933-022-01604-7","article-title":"Tirzepatide, a dual GIP\/GLP-1 receptor co-agonist for the treatment of type 2 diabetes with unmatched effectiveness regarding glycaemic control and body weight reduction.","volume":"21","author":"Nauck","year":"2022","journal-title":"Cardiovasc Diabetol"},{"key":"R48-20251216","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1001\/jamainternmed.2024.2525","article-title":"Semaglutide vs tirzepatide for weight loss in adults with overweight or obesity.","volume":"184","author":"Rodriguez","year":"2024","journal-title":"JAMA Intern Med"},{"key":"R49-20251216","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1056\/NEJMoa2416394","article-title":"Tirzepatide as compared with semaglutide for the treatment of obesity.","volume":"393","author":"Aronne","year":"2025","journal-title":"N Engl J Med"},{"key":"R50-20251216","first-page":"656","article-title":"FDA approves tirzepatide as first drug for obstructive sleep apnea.","volume":"333","author":"Anderer","year":"2025","journal-title":"JAMA"},{"key":"R51-20251216","doi-asserted-by":"crossref","first-page":"2143","DOI":"10.1001\/jama.2023.24539","article-title":"FDA green-lights tirzepatide, marketed as zepbound, for chronic weight management.","volume":"330","author":"Abbasi","year":"2023","journal-title":"JAMA"},{"key":"R52-20251216","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1056\/NEJMoa2301972","article-title":"Triple\u2013hormone-receptor agonist retatrutide for obesity\u2014a phase 2 trial.","volume":"389","author":"Jastreboff","year":"2023","journal-title":"N Engl J Med"},{"key":"R53-20251216","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1016\/S0140-6736(22)02033-5","article-title":"LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial.","volume":"400","author":"Urva","year":"2022","journal-title":"Lancet"},{"key":"R54-20251216","doi-asserted-by":"crossref","first-page":"2634","DOI":"10.1111\/dom.15184","article-title":"Orforglipron (LY3502970), a novel, oral non-peptide glucagon-like peptide-1 receptor agonist: a Phase 1a, blinded, placebo-controlled, randomized, single- and multiple-ascending-dose study in healthy participants.","volume":"25","author":"Pratt","year":"2023","journal-title":"Diabetes Obes Metab"},{"key":"R55-20251216","doi-asserted-by":"crossref","first-page":"29959","DOI":"10.1073\/pnas.2014879117","article-title":"Structural basis for GLP-1 receptor activation by LY3502970, an orally active nonpeptide agonist.","volume":"117","author":"Kawai","year":"2020","journal-title":"Proc Natl Acad Sci U S A"},{"key":"R56-20251216","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1007\/s13300-024-01554-1","article-title":"Effect of food consumption on the pharmacokinetics, safety, and tolerability of once-daily orally administered orforglipron (LY3502970), a non-peptide GLP-1 receptor agonist.","volume":"15","author":"Ma","year":"2024","journal-title":"Diabetes Ther"},{"key":"R59-20251216","doi-asserted-by":"crossref","first-page":"2642","DOI":"10.1111\/dom.15150","article-title":"Orforglipron (LY3502970), a novel, oral non-peptide glucagon-like peptide-1 receptor agonist: a Phase 1b, multicentre, blinded, placebo-controlled, randomized, multiple-ascending-dose study in people with type 2 diabetes.","volume":"25","author":"Pratt","year":"2023","journal-title":"Diabetes Obes Metab"},{"key":"R60-20251216","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1056\/NEJMoa2302392","article-title":"Daily oral GLP-1 receptor agonist orforglipron for adults with obesity.","volume":"389","author":"Wharton","year":"2023","journal-title":"N Engl J Med"},{"key":"R61-20251216","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1186\/s12933-025-02781-x","article-title":"Treatment with orforglipron, an oral glucagon like peptide-1 receptor agonist, is associated with improvements of CV risk biomarkers in participants with type 2 diabetes or obesity without diabetes.","volume":"24","author":"Wharton","year":"2025","journal-title":"Cardiovasc Diabetol"},{"key":"R62-20251216","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1056\/NEJMoa2505669","article-title":"Orforglipron, an oral small-molecule GLP-1 receptor agonist, in early type 2 diabetes.","volume":"393","author":"Rosenstock","year":"2025","journal-title":"N Engl J Med"},{"key":"R64-20251216","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1056\/NEJMoa2511774","article-title":"Orforglipron, an oral small-molecule GLP-1 receptor agonist for obesity treatment.","volume":"393","author":"Wharton","year":"2025","journal-title":"N Engl J Med"}],"container-title":["Cardiology in Review"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/CRD.0000000000001139","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T05:00:47Z","timestamp":1765861247000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/CRD.0000000000001139"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,16]]},"references-count":59,"URL":"https:\/\/doi.org\/10.1097\/crd.0000000000001139","relation":{},"ISSN":["1538-4683"],"issn-type":[{"value":"1538-4683","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,16]]}}}